We investigated the potential benefits of Myo-inositol, a naturally occurring sugar alcohol, on DU-145 prostate cancer cells. By treating these cancer cells with various doses of Myo-inositol, we determined its half-maximal inhibitory concentration (IC50) using a simple method that measures cell viability.
Our findings revealed that Myo-inositol significantly decreased the viability of DU-145 cells, showing an IC50 of 0.06 mg/ml. This suggests that Myo-inositol may effectively inhibit cancer cell growth.
Furthermore, we performed a detailed proteomic analysis using advanced techniques to explore how Myo-inositol changes protein expression. We found notable differences in protein levels between treated and untreated cells, particularly in areas linked to key cellular functions like cytoskeletal regulation, apoptosis (cell death), and stress responses. For instance, certain proteins tied to tumor suppression were upregulated in response to Myo-inositol treatment.
Overall, these observations highlight Myo-inositol's potential as a therapeutic option. However, further studies are necessary to unravel the underlying mechanisms and assess its effectiveness in combination with other treatments for managing prostate cancer, especially castration-resistant prostate cancer (CRPC).